Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Fitness-Based Induction Selection and Outcomes in Adult Acute Myeloid Leukemia at a Tertiary Cancer Center in Southern California

AML - 1566

Fitness-Based Induction Selection and Outcomes in Adult Acute Myeloid Leukemia at a Tertiary Cancer Center in Southern California

Jerry Qi

Poster Presenter: Jerry Qi

Thumbnail for Five-Year Survival Outcomes and Demographic Predictors in Marginal Zone Lymphoma: A SEER-Based Analysis

IBCL - 035

Five-Year Survival Outcomes and Demographic Predictors in Marginal Zone Lymphoma: A SEER-Based Analysis

Berkha Rani

Poster Presenter: Berkha Rani

Thumbnail for Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

IBCL - 334

Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-To-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis

Wenny Lin

Poster Presenter: Wenny Lin

Thumbnail for Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

AML - 1080

Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

Aakriti Adhikari

Poster Presenter: Aakriti Adhikari

Thumbnail for Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

CLL - 895

Fondaparinux vs Argatroban for Heparin-Induced Thrombocytopenia in Patients With Hematologic Malignancies: A Propensity-Matched Real-World Analysis

Ahmed Abbasi

Poster Presenter: Ahmed Abbasi

Thumbnail for Forecasting the Durability of Overall Survival Benefit With Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: A Cumulative and Forecast Meta-Analysis

AML - 1421

Forecasting the Durability of Overall Survival Benefit With Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: A Cumulative and Forecast Meta-Analysis

FNU Sagar

Poster Presenter: FNU Sagar

Thumbnail for Frailty and Outcomes With CAR-T Cell Therapy and Bispecific Antibodies in Hematologic Malignancies: A Scoping Review

ABCL - 1668

Frailty and Outcomes With CAR-T Cell Therapy and Bispecific Antibodies in Hematologic Malignancies: A Scoping Review

Yagnapriya Chirrareddy

Poster Presenter: Yagnapriya Chirrareddy

Thumbnail for Frailty and Survival Outcomes in Adult Acute Lymphoblastic Leukemia: A Real-World TriNetX Analysis

ALL - 380

Frailty and Survival Outcomes in Adult Acute Lymphoblastic Leukemia: A Real-World TriNetX Analysis

Nayanika Tummala

Poster Presenter: Nayanika Tummala

Thumbnail for Frailty as a Predictor of 30-Day Readmission in CAR-T Therapy Recipients

CT - 871

Frailty as a Predictor of 30-Day Readmission in CAR-T Therapy Recipients

Danielle Thor

Poster Presenter: Danielle Thor

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.